Hi All, this is probably a silly question but Ph1 trials are primarily about safety and ascertaining optimal dosage levels; without wanting to ignore any efficacy findings - Is it at all possible that if safety protocols are satisfactorily passed can future Ph.2 trials use cohorts that haven’t had their immune systems compromised by chemotherapy or other current SOC?
Ann: First patient dosed in Phase 1 bile tract cancer trial, page-134
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $396.8M | |||
| Open | High | Low | Value | Volume |
| 5.4¢ | 5.4¢ | 5.3¢ | $339.4K | 6.365M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 895592 | 5.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.4¢ | 672708 | 10 |
View Market Depth
| Last trade - 16.10pm 28/08/2024 (20 minute delay) ? |
| IMU (ASX) Chart |